Focus:
Early Stage Venture Capital Healthcare/Biotech.
Strategy:
Source local (Benelux/Europe) science and technology. Build, syndicate and leverage global expertise and network.
Team:
3 investment professionals, 2 venture partners and JV with Forbion (shared infrastructure, deal flow, mitigate syndication risk, leverage global network and know-how).
Track record:
Strong track record. Participated in 2 of Europe’s largest exits in 2015.
Risk:
Early stage risk is mitigated, shared with Dutch government via loan facility.
USP:
Big funding gap > opportunity to seed best in class early stage technologies and science > team has proven trackrecord to turn this into world’s leading BioTech companies.
More information
For more information about BioGeneration visit www.biogenerationventures.com
BioGeneration Ventures features
BioGeneration Ventures co-leads €25 million Series A fundraising in NorthSea Therapeutics and its promising NASH drug programma
December 14, 2017Read moreBGV co-leads €25 million Series A fundraising in NorthSea Therapeutics and its promising NASH drug programme Lead drug icosabutate, in-licensed from Pronova BioPharma AS...
0
BioGeneration Ventures Fund III reaches EUR 82 million in final close
October 31, 2017Read moreBioGeneration Ventures Fund III reaches EUR 82 million in final close Investments from Bristol-Myers Squibb and Johnson & Johnson Innovation – JJDC BioGeneration Ventures...
